A Phase II Trial of Rituximab in Combination with Pegfilgrastim in Patients with Indolent B-Cell Non-Hodgkin ’s Lymphoma

This phase 2 study demonstrates that augmenting neutrophil function by addition of pegfilgrastim can potentiate the clinical activity of rituximab in indolent B-cell non-Hodgkin ’s lymphomas (B-NHL) while retaining its excellent safety profile. Strategies to boost the innate immune system such as this combination warrant further study, especially in the frail, elderly population where therapeutic options are limited due to poor tolerance.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): AnnaLynn M. Williams, Andrea Baran, Carla Casulo, Patrick Reagan, Jonathan W. Friedberg, Margaret Helber, Jeremiah Moore, Elizabeth Baloga, Clive S. Zent, Paul M. BarrAbstractBackgroundAs oral targeted agents, such as ibrutinib, become more widely used understanding the impact of suboptimal dosing on overall and progression-free survival outside of clinical trials is imperative.MethodsData on ibrutinib discontinuation, dose reductions and treatment interruptions were collected on 170 non-Hodgkin lymphoma (NHL) and chr...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionBexarotene monotherapy is well-tolerated and has encouraging activity in PTCL that warrants further investigation. This agent should be considered for further prospective trials in this setting.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Ryan B. Sinit, Kathleen L. Horan, Russell K. Dorer, David M. AboulafiaAbstractIn 2016, the World Health Organization provisionally classified Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) as a lymphoid neoplasm under the subcategory of mature B-cell neoplasms. EBVMCU is manifested as a well-circumscribed ulcer, typically unifocal, and of the oropharynx, gastrointestinal tract, or skin. Immunohistochemical studies of these ulcers reveal monoclonal B-immunoblasts staining positively for CD20, CD30, EBER...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 October 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kristine A. Frerichs, Patricia W.C. Bosman, Inger S. Nijhof, S. Zweegman, Niels W.C.J. van de Donk
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusionsand Relevance: The combination of rituximab and bendamustine warrants further investigation in the treatment of HS, especially those originating from prior follicular lymphoma. Modern immunohistochemical and molecular profiling techniques are beginning to reveal heterogeneity amongst HS tumors and potentially therapeutic targets.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
AbstractPurpose of the ReviewThis review summarizes data about epidemiology, treatment, and risk factors for invasive fungal infections (IFI) in patients affected by chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and indolent non Hodgkin lymphoma (iNHL).Recent FindingsDespite advances in the prognosis and treatment of hematological malignancies in recent years, susceptibility to infection remains a significant challenge to patient care. A large amount of data regarding patients with acute leukemias have been published while little information is available on incidence of IFI in chronic lymphoproliferative disor...
Source: Current Fungal Infection Reports - Category: Infectious Diseases Source Type: research
In 2016, the World Health Organization provisionally classified Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) as a lymphoid neoplasm under the subcategory of mature B-cell neoplasms. EBVMCU is manifested as a well-circumscribed ulcer, typically unifocal, and of the oropharynx, gastrointestinal tract, or skin. Immunohistochemical studies of these ulcers reveal monoclonal B-immunoblasts staining positively for CD20, CD30, EBER, MUM-1, OCT-2, and PAX-5 and staining variably for BCL-6, CD15, CD45, and CD79a.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Histiocytic sarcoma (HS) is a rare aggressive malignancy with a dismal prognosis and no agreed upon standard treatment. Classically, the diagnosis of HS has been difficult to confirm and relied on inaccurate crude techniques. Therapy often involves intensive chemotherapeutic regimens, surgery, and/or radiation therapy, which are poorly tolerated with variable response rates. Patients often die of diffusely metastatic disease. Modern diagnostic techniques, are helping to slowly uncover more uniquely customized therapeutic approaches in this enigmatic disease.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
We report a case of symptomatic cytomegalovirus (CMV) reactivation upon initiation of daratumumab monotherapy treatment in a heavily pre-treated multiple myeloma (MM) patient.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Orally administered targeted therapies, including ibrutinib, are increasing used to treat non-Hodgkin lymphoma, however, little is known about the clinical impact of suboptimal dosing. Data on reasons and timeframes for ibrutinib discontinuation, dose reductions and treatment interruptions were collected on 170 non-Hodgkin lymphoma and chronic lymphocytic leukemia patients treated with ibrutinib at a single institution. Discontinuation of ibrutinib therapy was associated with poor outcome as previously reported. We also show that discontinuation of therapy for reasons other than progression and reduction of ibrutinib dose ...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma | Rituxan | Study